1. Home
  2. IONS
  3. IONS News

Latest Ionis Pharmaceuticals Inc. (IONS) News on January 19, 2025

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
IONS

PR Newswire

6 days ago

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
IONS

Zacks

10 days ago

Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
IONS

PR Newswire

10 days ago

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%?
IONS

Simply Wall St.

a month ago

Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%?

IONS

Morningstar Research

a month ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

IONS

Morningstar Research

a month ago

Analyst Report: Ionis Pharmaceuticals, Inc.

FDA approves Ionis’ TRYNGOLZA for FCS treatment
IONS

Pharmaceutical Technology

a month ago

FDA approves Ionis’ TRYNGOLZA for FCS treatment

Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
IONS

Zacks

a month ago

Ionis Gets FDA Approval for Rare Disease Drug Tryngolza

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
IONS

Benzinga

a month ago

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

Ionis gets a milestone approval; Another top FDA official to step down
IONS

BioPharma Dive

a month ago

Ionis gets a milestone approval; Another top FDA official to step down

IONS

MT Newswires

a month ago

Ionis Pharmaceuticals Says FDA Approved Familial Chylomicronemia Syndrome Drug

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
IONS

PR Newswire

a month ago

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?
IONS

Zacks

a month ago

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%
IONS

Zacks

a month ago

How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%

IONS

Morningstar Research

a month ago

Analyst Report: Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?
IONS

Zacks

a month ago

Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?

Theratechnologies enters exclusive licensing agreement with Ionis
IONS

TipRanks

a month ago

Theratechnologies enters exclusive licensing agreement with Ionis

IONS

MT Newswires

a month ago

Theratechnologies to Commercialize Two RNA-targeted Medicines in Canada

IONS

MT Newswires

a month ago

Theratechnologies Acquires Canadian Rights to 2 RNA Medicines From Ionis Pharmaceuticals

Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?
IONS

Zacks

2 months ago

Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?

Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?
IONS

Insider Monkey

2 months ago

Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?

Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now
IONS

Insider Monkey

2 months ago

Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now

Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
IONS

Zacks

2 months ago

Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks

Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
IONS

Simply Wall St.

2 months ago

Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
IONS

Zacks

2 months ago

Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus

Company News for Nov 7, 2024
IONS

Zacks

2 months ago

Company News for Nov 7, 2024

Ionis to present at upcoming investor conferences
IONS

PR Newswire

2 months ago

Ionis to present at upcoming investor conferences

Ionis announces design for Phase III trial of Angelman syndrome therapy
IONS

Clinical Trials Arena

2 months ago

Ionis announces design for Phase III trial of Angelman syndrome therapy

IONS

Thomson Reuters StreetEvents

2 months ago

Q3 2024 Ionis Pharmaceuticals Inc Earnings Call

Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ...
IONS

GuruFocus.com

2 months ago

Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ...

IONS

MT Newswires

2 months ago

Ionis Reports Late-Stage Trial Design in Angelman Syndrome

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
IONS

Motley Fool

2 months ago

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
IONS

Zacks

2 months ago

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
IONS

Zacks

2 months ago

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates

IONS

MT Newswires

2 months ago

Ionis Pharmaceuticals' Q3 Loss Narrows, Revenue Decreases

IONS

Associated Press Finance

2 months ago

Ionis Pharmaceuticals: Q3 Earnings Snapshot

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
IONS

PR Newswire

2 months ago

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Ionis reports third quarter 2024 financial results
IONS

PR Newswire

2 months ago

Ionis reports third quarter 2024 financial results

IONS

MT Newswires

2 months ago

Ionis Pharmaceuticals Gets FDA Acceptance of New Drug Application for Angioedema Treatment

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
IONS

PR Newswire

2 months ago

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE

Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
IONS

Zacks

2 months ago

Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
IONS

Zacks

3 months ago

Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IONS

Zacks

3 months ago

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ionis Pharmaceuticals' (NASDAQ:IONS) investors will be pleased with their 30% return over the last three years
IONS

Simply Wall St.

3 months ago

Ionis Pharmaceuticals' (NASDAQ:IONS) investors will be pleased with their 30% return over the last three years

Ionis to hold third quarter 2024 financial results webcast
IONS

PR Newswire

3 months ago

Ionis to hold third quarter 2024 financial results webcast

EU CHMP recommends AstraZeneca and Ionis’ Wainzua for ATTRv-PN
IONS

Pharmaceutical Technology

3 months ago

EU CHMP recommends AstraZeneca and Ionis’ Wainzua for ATTRv-PN

IONS

MT Newswires

3 months ago

Ionis Pharmaceuticals Says Wainzua Recommended for Approval in European Union

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
IONS

PR Newswire

3 months ago

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds
IONS

Insider Monkey

3 months ago

Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
IONS

GlobeNewswire

3 months ago

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
IONS

PR Newswire

4 months ago

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
IONS

Zacks

4 months ago

IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag

IONS

Morningstar Research

4 months ago

Analyst Report: Ionis Pharmaceuticals, Inc.

IONS

MT Newswires

4 months ago

Ionis Pharmaceuticals Says FDA Granted Fast Track Designation to Zilganersen to Treat Alexander Disease

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
IONS

PR Newswire

4 months ago

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease

The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly
IONS

The Wall Street Journal

4 months ago

The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly

Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
IONS

Zacks

4 months ago

Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering

IONS

MT Newswires

4 months ago

Update: Ionis Pharmaceuticals Shares Fall After Pricing of $500.3 Million Stock Offering

IONS

MT Newswires

4 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday

IONS

MT Newswires

4 months ago

Ionis Pharmaceuticals Prices $500.3 Million Public Offering at $43.50 a Share

Ionis announces pricing of $500.3 million public offering
IONS

PR Newswire

4 months ago

Ionis announces pricing of $500.3 million public offering

IONS

MT Newswires

4 months ago

Ionis Pharmaceuticals Plans $500 Million Common Stock Offering; Shares Fall After Hours

Ionis announces proposed public offering of common stock
IONS

PR Newswire

4 months ago

Ionis announces proposed public offering of common stock

Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?
IONS

Zacks

4 months ago

Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?

Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
IONS

Zacks

4 months ago

Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
IONS

GlobeNewswire

4 months ago

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
IONS

GlobeNewswire

4 months ago

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

Ionis to present at upcoming investor conferences
IONS

PR Newswire

5 months ago

Ionis to present at upcoming investor conferences

Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
IONS

Zacks

5 months ago

Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?

Insider Sale at Ionis Pharmaceuticals Inc (IONS) by EVP, Chief Development Officer Richard Geary
IONS

GuruFocus.com

5 months ago

Insider Sale at Ionis Pharmaceuticals Inc (IONS) by EVP, Chief Development Officer Richard Geary

Ionis Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
IONS

Simply Wall St.

6 months ago

Ionis Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations

IONS

Morningstar Research

6 months ago

Analyst Report: Ionis Pharmaceuticals, Inc.

Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises
IONS

Zacks

6 months ago

Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises

IONS

MT Newswires

6 months ago

BMO Capital Downgrades Ionis Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $60 From $67

IONS

Thomson Reuters StreetEvents

6 months ago

Q2 2024 Ionis Pharmaceuticals Inc Earnings Call

Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
IONS

Zacks

6 months ago

Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

IONS

MT Newswires

6 months ago

Ionis Pharmaceuticals' Q2 loss Narrows as Revenue Increases

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
IONS

Zacks

6 months ago

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates

IONS

Associated Press Finance

6 months ago

Ionis Pharmaceuticals: Q2 Earnings Snapshot

Ionis reports second quarter 2024 financial results
IONS

PR Newswire

6 months ago

Ionis reports second quarter 2024 financial results

Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
IONS

PR Newswire

6 months ago

Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IONS

Zacks

6 months ago

Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
IONS

Zacks

6 months ago

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?

IONS

MT Newswires

6 months ago

Leerink Partners Upgrades Ionis Pharmaceuticals to Outperform From Market Perform, Adjusts PT to $62 From $53

Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
IONS

Zacks

6 months ago

Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study

Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug
IONS

Clinical Trials Arena

6 months ago

Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
IONS

Investor's Business Daily

6 months ago

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

IONS

MT Newswires

6 months ago

Sector Update: Health Care Stocks Higher Monday Afternoon

IONS

MT Newswires

6 months ago

Ionis Pharmaceuticals Shares Rise After Positive Results for Angelman Syndrome Drug Study

Ionis plots next steps for Angelman drug Biogen passed on
IONS

BioPharma Dive

6 months ago

Ionis plots next steps for Angelman drug Biogen passed on

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
IONS

PR Newswire

6 months ago

Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome

Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
IONS

Zacks

6 months ago

Ionis (IONS) Completes Enrolment for Rare Disease Drug Study

Ionis to hold second quarter 2024 financial results webcast
IONS

PR Newswire

6 months ago

Ionis to hold second quarter 2024 financial results webcast

Ionis completes subject enrolment in Alexander disease treatment trial
IONS

Clinical Trials Arena

6 months ago

Ionis completes subject enrolment in Alexander disease treatment trial

IONS

MT Newswires

6 months ago

Ionis Pharmaceuticals Completes Trial Enrollment for Alexander Disease Treatment

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
IONS

PR Newswire

6 months ago

Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease

Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
IONS

Zacks

6 months ago

Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?

Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
IONS

PR Newswire

6 months ago

Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome

IONS

MT Newswires

7 months ago

Stifel Adjusts Ionis Pharmaceuticals Price Target to $53 From $50, Maintains Hold Rating

FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
IONS

Zacks

7 months ago

FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen

Share on Social Networks: